As the European markets continue to show signs of steady growth, buoyed by looser monetary policy and positive economic indicators, investors are increasingly on the lookout for stocks that may be trading below their estimated value. In this context, identifying undervalued stocks involves assessing companies with strong fundamentals and potential for growth despite current market fluctuations.
Top 10 Undervalued Stocks Based On Cash Flows In Europe
| Name |
Current Price |
Fair Value (Est) |
Discount (Est) |
|---|---|---|---|
| Sanoma Oyj (HLSE:SANOMA) |
€9.21 |
€18.40 |
49.9% |
| Redelfi (BIT:RDF) |
€11.70 |
€23.30 |
49.8% |
| Outokumpu Oyj (HLSE:OUT1V) |
€4.278 |
€8.48 |
49.6% |
| LINK Mobility Group Holding (OB:LINK) |
NOK32.95 |
NOK65.74 |
49.9% |
| Hemnet Group (OM:HEM) |
SEK170.90 |
SEK337.22 |
49.3% |
| Exail Technologies (ENXTPA:EXA) |
€84.10 |
€167.48 |
49.8% |
| Cyber_Folks (WSE:CBF) |
PLN201.50 |
PLN397.65 |
49.3% |
| cyan (XTRA:CYR) |
€2.26 |
€4.50 |
49.8% |
| Artifex Mundi (WSE:ART) |
PLN12.20 |
PLN24.36 |
49.9% |
| Allegro.eu (WSE:ALE) |
PLN30.625 |
PLN60.22 |
49.1% |
Let's take a closer look at a couple of our picks from the screened companies.
Netcompany Group
Overview:Netcompany Group A/S delivers business critical IT solutions to private and public sectors across various countries including Denmark, Norway, the UK, and others, with a market cap of DKK15.95 billion.
Operations:Revenue Segments (in millions of DKK): Netcompany Group A/S generates its revenue by providing essential IT solutions to both private and public sector clients across Denmark, Norway, the United Kingdom, the Netherlands, Greece, Belgium, Luxembourg, and other international markets.
Estimated Discount To Fair Value:20.9%
Netcompany Group is trading at DKK 347.2, significantly below its estimated fair value of DKK 438.93, suggesting undervaluation based on cash flows. Despite a recent net loss and reduced profit margins, the company forecasts robust earnings growth of 63.7% annually, outpacing the Danish market's average. Revenue growth is also expected to be strong at 11.5% per year. However, high debt levels remain a concern amidst these positive projections for future profitability and revenue expansion.
-
Our growth report here indicates Netcompany Group may be poised for an improving outlook.
-
Take a closer look at Netcompany Group's balance sheet health here in our report.
Peab
Overview:Peab AB (publ) is a construction and civil engineering company operating in Sweden, Norway, Finland, Denmark, and internationally with a market cap of SEK24.09 billion.
Operations:The company's revenue segments include Industry at SEK20.49 billion, Construction at SEK23.05 billion, Civil Engineering at SEK17.24 billion, Project Development - Housing Development at SEK3.59 billion, and Project Development - Property Development at SEK777 million.
Estimated Discount To Fair Value:35.8%
Peab is trading at SEK 84.45, well below its estimated fair value of SEK 131.63, highlighting potential undervaluation based on cash flows. Despite a low forecasted return on equity and unstable dividend history, Peab's earnings are expected to grow significantly at over 21% annually, surpassing the Swedish market average. Recent contract extensions and new projects worth billions further bolster its order book, although interest coverage remains a concern for financial stability.
Sandoz Group
Overview:Sandoz Group AG is a global company that develops, manufactures, and markets generic pharmaceuticals and biosimilars, with a market cap of CHF25.25 billion.
Operations:The company generates revenue of $10.59 billion from its Pharmaceuticals segment, which includes generic pharmaceuticals and biosimilars.
Estimated Discount To Fair Value:32.4%
Sandoz Group's current share price of CHF 58.62 is significantly below its fair value estimate of CHF 86.76, suggesting undervaluation based on cash flows. Despite interest payments not being well covered by earnings, the company's earnings are projected to grow at a robust 29.58% annually, outpacing the Swiss market average. Recent European launches of key biosimilars like Wyost and Jubbonti enhance Sandoz's growth prospects in oncology and immunology sectors amidst regulatory challenges in the US market for certain products.
Seize The Opportunity
-
Click through to start exploring the rest of the 191 Undervalued European Stocks Based On Cash Flows now.
-
Have you diversified into these companies? Leverage the power of Simply Wall St's portfolio to keep a close eye on market movements affecting your investments.
-
Take control of your financial future using Simply Wall St, offering free, in-depth knowledge of international markets to every investor.
Ready To Venture Into Other Investment Styles?
-
Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
-
Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
-
Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management .
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include CPSE:NETC OM:PEAB B and SWX:SDZ.
This article was originally published by Simply Wall St .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
